• Explore /
  • Poster
  • / Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.

Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.

Abstract Poster

Authors

null

Anthony H Kong

King's College London, London, United Kingdom

Anthony H Kong , Marielle S Klein Hesselink , Begoña Aguilera , Douglas Adkins , Caroline Even , Jerome Fayette , Jameel Muzaffar , Sonja Visscher , Cornelis JM Melief , Leon W. Hooftman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04398524

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6028)

DOI

10.1200/JCO.2023.41.16_suppl.6028

Abstract #

6028

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Talal El Zarif

First Author: Yoshiaki Nakamura

First Author: Gustavo Schvartsman

First Author: Nadezhda Omelchenko